

The Pharmacy Careers Summit is the virtual event for pharmacists, interns, and students looking to explore career opportunities. Join Australia's top pharmacy employers, peak industry bodies and leaders for one powerful day of career inspiration, connections and practical insights. With auditorium presentations, expo halls, a live leaderboard with prizes up for grabs - PCS26 is the must-attend event of the year. It's all happening **Friday, 10 July!**

[Register Today!](#)

Leaders Panel

The big picture, the future of Pharmacy, from Australia's Pharmacy Leaders



Adjunct Professor
Trent Twomey
National President,
Pharmacy Guild of Australia



Professor Mark Naunton
National President,
Pharmaceutical Society of Australia



Tom Simpson
President,
Advanced Pharmacy Australia

Connect at the Trade Exhibition

The PCS26 Trade Exhibition connects you directly with many of Australia's most prominent pharmacy employers and organisations. Whether you're pursuing an intern placement, pharmacist role, or exploring ownership and entrepreneurial opportunities, this is the essential annual gathering for anyone shaping a career in the profession. Register today!

Featured Exhibitors



Exhibitors



For every attendee, \$5 will be donated to the PSS, [register today!](#)



An Extensive Program of Speakers

Building on the momentum of the previous annual award-winning summits - Best Event APAC (2025) and Best Summit (2024) at the Eventeer Awards - PCS26 will once again deliver an extensive program featuring speakers across industry, clinical practice, business, leadership, and personal development. Every session is designed to equip attendees with practical insights and forward-looking guidance to support their next career step. Register today!

Get ready to hear from these speakers and organisations, and more, live in the auditorium



For every attendee, \$5 will be donated to the PSS, [register today!](#)



Friday, 10th July 2026

FREE Virtual Summit

www.pharmacycareerssummit.com.au



From **full** to **free...**
Fast relief from constipation for over 30 years.

Australia's **No.1** glycerol suppository range **Petrus**

Today's issue of PD

Pharmacy Daily today features two pages of news, plus a front cover page from the **Pharmacy Careers Summit 2026**, and a full page from **TerryWhite Chemmart**.

Leaders panel

MAKE sure you catch the leaders panel at the upcoming Pharmacy Careers Summit, featuring Professor Mark Naunton, Professor Trent Twomey and Associate Professor Tom Simpson - see the **cover page** for more.

Join the future

TERRYWHITE Chemmart is leading the full-scope future with its Pathway to Prescribing program - learn more on **page three**.

PSA branch leaders announced

THE Pharmaceutical Society of Australia (PSA) has announced the branch committee presidents and vice presidents recently elected to serve for the term commencing 01 Jul 2026, with a mix of returning and newly elected leadership officials.

The Queensland branch has seen former vice president James Buckley elected president, with Sue Carson and Kate Gunthorpe newly elected vice presidents.

In South Australia and Northern Territory, former committee members Bec Rogers and Lauren Fraser have been elected president and vice president respectively, with PSA Pharmacist of the Year 2025 Jaimee Anderson newly elected to leadership as vice president.

Vice president for the Victorian branch David Froom is a new face on the leadership team, joining re-elected president Tinu Abraham and fellow vice president Kate Wang.

The ACT, NSW, Tasmania and WA



teams remain unchanged, and are as follows:

- ACT - president Erin Cooper; vice presidents Olivia Collette and Andrew Kelly
- NSW - president Luke Kelly; vice presidents Rebekah Moles and Lily Pham
- Tasmania - president Joanne Gross; vice presidents David Peachey and Nicole Dilworth
- WA - president Kristian Ray; vice presidents Ayomide Ogundipe and Phuong Nguyen.

PSA national president Professor Mark Naunton congratulated the newly elected and returning leadership officials on their appointments.

"PSA's branch committees represent a strong, diverse leadership group with a breadth and depth of experiences across all practice areas," he said.

"Their leadership will ensure the voices of pharmacists within their branches are heard as they embark on their advocacy efforts for the profession.

"We thank those who have been re-elected for their ongoing commitment to the PSA and the profession, and welcome those newly elected officials as they step into these important leadership positions," he concluded. *KB*

Be alert to potential fraud, says PDL

PHARMACEUTICAL Defence Limited (PDL) has urged pharmacists to pause before dispensing as it continues to receive reports of forged prescriptions, identity fraud and patient misrepresentation (*PD* 17 Dec 2024).

The indemnity insurer acknowledged fraud is not always easy to detect, noting forgery is only one part of the problem and pharmacists also come across customers who misrepresent identity, authority or clinical need to obtain high-risk medicines.

A rushed decision or missed red flag can lead to inappropriate supply, with PDL recommending pharmacists be alert to red flags such as urgency on the part of the patient, an unfamiliar person collecting or inconsistent detail.

Other essential steps include verifying identity and authority to collect, checking real-time prescription monitoring programs and dispensing history, and contacting the prescriber if needed.

If pharmacists still have concerns, they should consider limited supplies (where appropriate and permitted) or not supplying at all.

PDL also recommended reporting what was presented, checks undertaken and reasoning for decisions, and members should submit and incident report to PDL.

Learn more **HERE**.

Tavneos under scrutiny in the US/EU

CSL yesterday issued an ASX announcement informing investors that the European Medicines Agency (EMA) has recommended the revocation of EU marketing authorisation for Tavneos (avacopan).

The drug is indicated for the treatment of adults with severe active ANCA-associated vasculitis, which has few treatment options.

The EMA has raised concerns about the handling of data in the pivotal clinical trial supporting the product's approval.

The US Food and Drug Administration (FDA) has also suggested it may withdraw Tavneos from the market, stating, "New information indicates that Tavneos has not been shown to be effective for its approved use, and because the application that resulted in FDA approval contained untrue statements of material fact."

Tavneos is approved and PBS-listed in Australia - the TGA told *Pharmacy Daily* it is aware of developments overseas.



Payday super is here

Free resources for small business

From 1 July 2026, super must be paid on payday.

COSBOA's free Small Business **PEAK** program gives small business owners the expert guidance, tools and training to get it right, without the cost. Whether for your own business or someone in your network, **PEAK** is the practical support small business needs right now.





Dispensary Corner

TWO of the most polarising greens, spinach and kale, are said to be able to cut the risk of chronic lung disease, according to a new study from Edith Cowan University.

Research found those who eat more foods which are rich in vitamin K1, such as leafy green vegetables, may lower their risk of the disease.

The study saw researchers from ECU's Nutrition & Health Innovation Research Institute look at the two main forms of vitamin K in our diet: K1, which is found in foods like spinach, kale, and broccoli; and K2, found in meat, eggs, and dairy.

They discovered those who ate the most vitamin K1 were less likely to develop a chronic obstructive pulmonary disease.

The study found those with the highest intake of vitamin K1 had about a 16% lower risk of COPD compared to those eating the least.

"Just one extra serve of leafy greens like kale, about one and a half to two cups a day, is an achievable way to boost your vitamin K1 intake," ECU researcher Chengfeng Li said.

Almost half a million Aussies have COPD, a life-threatening and worsening lung condition that makes it hard to breathe.



Major SAO changes for OTPs

THE Australian Pharmacy Council (APC) has introduced a new policy allowing overseas-trained pharmacists (OTPs) to renew their Skills Assessment Outcome (SAO) beyond the initial three years.

The change, which takes effect from tomorrow, means pharmacists who have successfully completed an APC exam and received an SAO can apply for a renewal with a three-year validity period, with applicants able to renew as many times as needed.

Candidates who have passed an APC exam will not need to re-sit it, but renewal fees for the SAO will still be payable.

The new policy gives OTPs more time to secure visas and internship opportunities, helping reduce time pressures and costs.

APC chief standards officer Kate Spencer said the policy was developed in close consultation with the Pharmacy Board of Australia and Ahpra to support candidates on their pathway to registration.

"We recognise that overseas-trained pharmacists can face complex pathways when pursuing internship opportunities and visa arrangements, alongside navigating the validity period of their SAO for Department of Home Affairs requirements," Spencer said.

"While APC does not influence employment or visa processes, we have worked closely with our stakeholders to strengthen the SAO framework.

"This change aims to reduce costs and timing pressures, streamline key processes, and maintain the high professional standards



expected within Australia's healthcare system," she said.

In addition to SAO renewals, APC has introduced further enhancements designed to improve the candidate experience, including expanded payment options and system upgrades.

"Overseas-trained pharmacists play an important role in Australia's healthcare system, particularly in rural and regional communities where access to services can be limited," Spencer said, adding that employment outcomes remain outside APC's remit. *KB*

New scripts increase falls risk

OLDER adults discharged from hospital with a new prescription for a sedative, especially a benzodiazepine or antipsychotic, are at increased risk of falls and other negative consequences, according to new research published yesterday in the *Canadian Medical Association Journal*.

The study included more than 1.86 million adults aged 66 years and older, and found that 13% (246,000) filled at least one prescription for any sedative within seven days of discharge, with a 20% increased risk of falls.

"Given the identified associations, clinicians must consider whether new sedative prescriptions are essential or can be deprescribed or de-escalated before or shortly after hospital discharge," the authors concluded.

Access the study [HERE](#).

DID YOU KNOW?

That we regularly publish **Health Professional only** editions of *Pharmacy Daily*?

CLICK HERE TO UPDATE YOUR DETAILS

Pharmacy Daily



Join the brand that's leading the Future of Pharmacist Prescribing.

Pharmacist Prescribing



Becoming a Pharmacist Prescriber was a defining step in my career. With TerryWhite Chemmart's Pathway to Prescribing program, I had the structure, mentorship and confidence to qualify and practise at full scope. It has completely transformed the way I care for my patients.

Maree Keating,
TerryWhite Chemmart Upper Kedron



Speak to our team about joining the TWC Pharmacy Network today and ask about our Performance Promise.

Richard Jensch	(QLD, NT)	0401 560 712
Fiona McKenzie	(ACT, NSW)	0437 599 920
Peter O'Brien	(VIC, TAS)	0427 352 902
Jordan Hall	(WA, SA)	0419 866 587



Scan to discover more ways in which TerryWhite Chemmart is here to support you
Or visit dedicatedtocare.com.au



Dedicated to *Care*